Author:
Huang Jing,Zhu Honglin,Liu Sijia,Li Mengtao,Li Yisha,Luo Hui,Zuo Xiaoxia
Abstract
Abstract
Background
Pulmonary arterial hypertension (PAH) and interstitial lung disease (ILD) are leading causes of systemic sclerosis (SSc)-related death. In this study, we aimed to identify biomarkers for detecting SSc pulmonary complications that are mild and in the early stages to improve the prognosis.
Methods
We screened for serum biomarkers using a proteomic antibody microarray that simultaneously assessed 1000 proteins. Differentially expressed proteins were further verified using ELISA. Finally, we performed a correlation analysis using clinical data.
Results
We identified 125 differentially expressed proteins, of which calcitonin, sclerostin (SOST), CD40, and fibronectin were selected for further verification. Serum calcitonin and SOST levels were significantly elevated in all SSc pulmonary complication subgroups, whereas serum calcitonin levels were higher in the SSc with PAH subgroup than in the SSc without PAH and ILD subgroup. Serum SOST levels were possibly associated with the presence of ILD and positively related to the presence of cardiac and gastrointestinal involvement. Serum CD40 and calcitonin levels appeared to be positively related to the presence of renal involvement, and serum calcitonin was also positively related to the presence of gastrointestinal involvement.
Conclusions
This study indicated that serum calcitonin and SOST levels may be promising biomarkers for SSc-related PAH and ILD, respectively. Further research is needed to verify this result and understand the underlying mechanisms.
Funder
CAMS Innovation Fund for Medical Sciences
Publisher
Springer Science and Business Media LLC
Reference51 articles.
1. Mouawad JE, Feghali-Bostwick C. The molecular mechanisms of systemic sclerosis-associated lung fibrosis. Int J Mol Sci. 2023;24(3):2693.
2. Barkhane Z, Nimerta F, Zulfiqar S, Dar S, Afzal MS, Zaree A, Adwani R, Palleti SK. Independent predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: a systematic review and meta-analysis. Cureus. 2023;15(5):e39730.
3. Elhai M, Meune C, Boubaya M, Avouac J, Hachulla E, Balbir-Gurman A, Riemekasten G, Airò P, Joven B, Vettori S, et al. Mapping and predicting mortality from systemic sclerosis. Ann Rheum Dis. 2017;76(11):1897–905.
4. Rahaghi FF, Hsu VM, Kaner RJ, Mayes MD, Rosas IO, Saggar R, Steen VD, Strek ME, Bernstein EJ, Bhatt N, et al. Expert consensus on the management of systemic sclerosis-associated interstitial lung disease. Respir Res. 2023;24(1):6.
5. Ngo K. Systemic sclerosis and pulmonary disease. Adv Exp Med Biol. 2021;1303:173–82.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献